Corvus Pharmaceuticals, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CRVS, updated each market day.
CRVS AI Sentiment
AI sees no strong directional signal for Corvus Pharmaceuticals, Inc. stock over the next 10 market days.
Prediction date: Oct. 12, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Sector
Exchange
Market Cap
$858,874,838
Cap Tier
Employees
37
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
March 23, 2016
Website
CRVS Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CRVS Volatility
Corvus Pharmaceuticals, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
